Glucagon‐like peptide agonists for weight management in antipsychotic‐induced weight gain: A systematic review and meta‐analysis

Abstract

AbstractIntroductionManaging body weight in patients with antipsychotic‐induced weight gain (AIWG) is challenging. Besides lifestyle interventions, pharmacological interventions may contribute to weight loss. This systematic review and meta‐analysis evaluated the effect on weight loss and adverse effects of glucagon‐like peptide‐1 (GLP‐1) agonists in patients with AIWG.Materials and MethodsFollowing PRISMA guidelines, we performed a meta‐analysis of blinded and open‐label randomised controlled trials (RCTs), non‐randomised controlled trials and cohort studies that evaluated treatment with GLP‐1 in patients with AIWG, regardless of psychiatric diagnosis. PubMed, Embase, PsycINFO and Cochrane Library databases were searched. Primary outcome measures were changes in body weight and BMI. Secondary outcomes were changes in adverse effects and severity of psychopathology due to GLP‐1 agonists.ResultsOnly data for exenatide and liraglutide could be included, that is, five RCTs and one cohort study. For exenatide the mean weight loss was −2.48 kg (95% Confidence Interval (CI) −5.12 to +0.64; p = 0.07), for liraglutide the mean weight loss was −4.70 kg (95% CI −4.85 to −4.56; p < 0.001). The mean change in BMI was −0.82 (95% CI −1.56 to −0.09; p = 0.03) in the exenatide groups and −1.52 (95% CI −1.83 to −1.22; p < 0.001) in the liraglutide groups. Exenatide and liraglutide did not adversely affect psychopathology. The most common adverse events were nausea, vomiting, and diarrhoea.ConclusionThe GLP‐1 agonists exenatide and liraglutide are promising drugs for inducing weight loss in patients with AIWG. The adverse effects are acceptable, and the addition of GLP‐1 does not increase the severity of psychopathology. However, more research is needed.